Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 8;39(11):1442-1444.
doi: 10.1016/j.ccell.2021.09.015. Epub 2021 Oct 19.

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma

Adolfo Aleman  1 , Bhaskar Upadhyaya  2 , Kevin Tuballes  3 , Katerina Kappes  2 , Charles R Gleason  4 , Katherine Beach  4 , Sarita Agte  2 , Komal Srivastava  4 ; PVI/Seronet Study Group; Oliver Van Oekelen  1 , Vanessa Barcessat  3 , Nina Bhardwaj  5 , Seunghee Kim-Schulze  6 , Sacha Gnjatic  7 , Brian Brown  8 , Carlos Cordon-Cardo  9 , Florian Krammer  4 , Miriam Merad  10 , Sundar Jagannath  2 , Ania Wajnberg  11 , Viviana Simon  12 , Samir Parekh  13
Collaborators, Affiliations

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma

Adolfo Aleman et al. Cancer Cell. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Viviana Simon and Carlos Cardo-Cordon are listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020) and is currently consulting for Seqirus and Avimex. The Krammer laboratory is collaborating with Pfizer on animal models of SARS-CoV-2. Sundar Jagannath reports consulting fees from Bristol Myers Squibb (Celgene), Janssen, Karyopharm Therapeutics, Merck, Sanofi, and Takeda Pharmaceuticals. Samir Parekh reports consulting fees from Foundation Medicine. Sacha Gnjatic reports past consultancy and/or advisory roles for Merck and OncoMed and past or current research funding from Bristol-Myers Squibb, Genentech, Boehringer-Ingelheim, Pfizer, Takeda, and Regeneron. Nina Bhardwaj reports consultancy and/or advisory roles for Novartis, Apricity, Rome Therapeutics, CureVac, Genotwin, BioNTech, Gildea, Tempest Therapeutics, Boehringer Ingelheim, and Rubis Therapeutics. Other authors report no relevant conflicts of interest.

References

    1. Apostolidis S.A., Kakara M., Painter M.M., Goel R.R., Mathew D., Lenzi K., Rezk A., Patterson K.R., Espinoza D.A., Kadri J.C., et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat. Med. 2021 doi: 10.1038/s41591-021-01507-2. - DOI - PMC - PubMed
    1. Bakouny Z., Hawley J.E., Choueiri T.K., Peters S., Rini B.I., Warner J.L., Painter C.A. COVID-19 and Cancer: Current Challenges and Perspectives. Cancer Cell. 2020;38:629–646. doi: 10.1016/j.ccell.2020.09.018. - DOI - PMC - PubMed
    1. Duvall M.G., Precopio M.L., Ambrozak D.A., Jaye A., McMichael A.J., Whittle H.C., Roederer M., Rowland-Jones S.L., Koup R.A. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur. J. Immunol. 2008;38:350–363. doi: 10.1002/eji.200737768. - DOI - PMC - PubMed
    1. Ehmsen S., Asmussen A., Jeppesen S.S., Nilsson A.C., Østerlev S., Vestergaard H., Justesen U.S., Johansen I.S., Frederiksen H., Ditzel H.J. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell. 2021;39:1034–1036. doi: 10.1016/j.ccell.2021.07.016. - DOI - PMC - PubMed
    1. Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., Rawlings S.A., Sutherland A., Premkumar L., Jadi R.S., et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181:1489–1501.e15. doi: 10.1016/j.cell.2020.05.015. - DOI - PMC - PubMed

Publication types

MeSH terms